Immune Design Corp. (NASDAQ:IMDZ) was downgraded by research analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a report released on Saturday, August 5th.
Several other analysts have also recently issued reports on IMDZ. ValuEngine upgraded shares of Immune Design Corp. from a “strong sell” rating to a “sell” rating in a research note on Thursday, June 22nd. Jefferies Group LLC reiterated a “buy” rating and issued a $18.00 target price on shares of Immune Design Corp. in a research note on Wednesday, June 28th. Cowen and Company reiterated a “buy” rating on shares of Immune Design Corp. in a research note on Tuesday, June 6th. Finally, Zacks Investment Research upgraded shares of Immune Design Corp. from a “sell” rating to a “hold” rating in a research note on Thursday, May 18th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $14.50.
Immune Design Corp. (IMDZ) opened at 8.15 on Friday. The firm’s market capitalization is $208.79 million. The firm’s 50-day moving average is $9.84 and its 200 day moving average is $7.33. Immune Design Corp. has a 12 month low of $4.50 and a 12 month high of $13.05.
Immune Design Corp. (NASDAQ:IMDZ) last posted its earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.65) by $0.11. Immune Design Corp. had a negative net margin of 324.33% and a negative return on equity of 59.14%. The business had revenue of $0.73 million for the quarter, compared to analysts’ expectations of $1.50 million. On average, analysts expect that Immune Design Corp. will post ($2.34) EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This story was first reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this story on another site, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The original version of this story can be viewed at https://stocknewstimes.com/2017/08/18/immune-design-corp-imdz-rating-lowered-to-buy-at-bidaskclub-updated.html.
In related news, Director Lewis W. Coleman acquired 12,000 shares of the stock in a transaction dated Tuesday, July 11th. The shares were purchased at an average price of $9.05 per share, for a total transaction of $108,600.00. Following the transaction, the director now owns 40,000 shares in the company, valued at approximately $362,000. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Lewis W. Coleman acquired 8,000 shares of the stock in a transaction dated Friday, July 7th. The shares were bought at an average price of $9.27 per share, for a total transaction of $74,160.00. Following the transaction, the director now owns 40,000 shares in the company, valued at approximately $370,800. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 30,000 shares of company stock worth $272,760. Corporate insiders own 42.90% of the company’s stock.
Hedge funds have recently bought and sold shares of the stock. Bank of America Corp DE boosted its stake in Immune Design Corp. by 123.3% in the first quarter. Bank of America Corp DE now owns 15,246 shares of the biotechnology company’s stock valued at $104,000 after buying an additional 8,418 shares during the period. State of Wisconsin Investment Board bought a new stake in Immune Design Corp. during the second quarter valued at $117,000. Alliancebernstein L.P. bought a new stake in Immune Design Corp. during the second quarter valued at $118,000. Virtu KCG Holdings LLC bought a new stake in Immune Design Corp. during the second quarter valued at $153,000. Finally, Trexquant Investment LP acquired a new position in Immune Design Corp. during the first quarter valued at approximately $183,000. Hedge funds and other institutional investors own 50.82% of the company’s stock.
About Immune Design Corp.
Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.
Receive News & Ratings for Immune Design Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design Corp. and related companies with MarketBeat.com's FREE daily email newsletter.
